title: Characteristics of candidates for lung transplantation due to chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency emphysema.
abstract: BACKGROUND
  COPD and emphysema due to alpha-1 antitrypsin deficiency (AATD) are the first and fourth indications for lung transplantation worldwide, respectively. Despite this, there is little information regarding the health status of these patients at the time of transplantation.
  
  
  METHODS
  Patients who received a lung transplant in the Hospital Vall d'Hebron between July 1993 and August 2013 were identified and data from the evaluation prior to the transplant were collected.
  
  
  RESULTS
  A total of 217 patients who received a lung transplant for COPD and 19 in whom the indication was AATD were included. These patients were severely impaired at the time of the evaluation for lung transplantation, although the trend in recent years has been to evaluate patients at earlier stages of the disease. Baseline characteristics were similar in both groups except that patients with AATD were younger [43 (7.7) vs. 53.6 (6.1) years old, P<.001], with less exposure to tobacco [23.9 (15) vs. 50 (29) packs-year, P<002] and lower PCO2 [41.7 (7.6) vs. 47.9 (9.7) mmHg, P<.004].
  
  
  CONCLUSIONS
  The number of patients receiving a lung transplant for COPD has progressively increased and the tendency is to perform the evaluation in earlier stages of the disease. Patients receiving transplants for COPD and AATD had similar characteristics at the time of the evaluation, although AATD patients were younger and had less exposure to tobacco and lower PCO2.
authors.affiliation: Servicio de Neumología, Universidad de Sassari, Sassari, Italia.
authors.forename: Daniela
authors.initials: D
authors.lastname: Giacoboni
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Miriam
authors.initials: M
authors.lastname: Barrecheguren
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Cristina
authors.initials: C
authors.lastname: Esquinas
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Esther
authors.initials: E
authors.lastname: Rodríguez
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Cristina
authors.initials: C
authors.lastname: Berastegui
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Manuel
authors.initials: M
authors.lastname: López-Meseguer
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Víctor
authors.initials: V
authors.lastname: Monforte
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Bravo
authors.affiliation: Servicio de Neumología, Universidad de Sassari, Sassari, Italia.
authors.forename: Pietro
authors.initials: P
authors.lastname: Pirina
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España. Electronic address: mmiravitlles@vhebron.net.
authors.forename: Marc
authors.initials: M
authors.lastname: Miravitlles
authors.affiliation: Servicio de Neumología, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, España.
authors.forename: Antonio
authors.initials: A
authors.lastname: Román
mesh_terms: D017677:Age Distribution; D002245:Carbon Dioxide / Q000097:blood; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D006801:Humans; D016040:Lung Transplantation / Q000706:statistics & numerical data / Q000639:trends; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010102:Oxygen Inhalation Therapy / Q000706:statistics & numerical data; D010313:Partial Pressure; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000453:epidemiology / Q000601:surgery* / Q000628:therapy; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D012907:Smoking / Q000453:epidemiology; D013030:Spain / Q000453:epidemiology; D019896:alpha 1-Antitrypsin Deficiency / Q000097:blood / Q000453:epidemiology / Q000601:surgery* / Q000628:therapy
chemical_list: D002245:Carbon Dioxide; D010100:Oxygen
keywords: Alpha-1 antitrypsin deficiency; COPD; Déficit de alfa-1 antitripsina; EPOC; Lung trasnplantation; Trasplante pulmonar